A total of 87% of patients with low levels of Survivin expression achieved good response to nCRT; at the same time, only 50% of the patients with high levels of Survivin in their tumor tissue responded well to the treatment (p = 0.02). This evidence concerns the gene BIRC5 and neoplasm.